Digital image analysis outperforms manual biomarker assessment in breast cancer

Modern Pathology

Volumn 29, Issue 4, 2016, Pages 318-329

  Stålhammar, Gustav ^a,b   Fuentes Martinez, Nelson ^a,c   Lippert, Michael ^d   Tobin, Nicholas P ^e   Mølholm, Ida ^d,f   Kis, Lorand ^g   Rosin, Gustaf ^a   Rantalainen, Mattias ^a   Pedersen, Lars ^d   Bergh, Jonas ^a,e   Grunkin, Michael ^d   Hartman, Johan ^a,e,g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ST ERIK S EYE HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d Visiopharm A/S   (Denmark)

^e Cancer Center Karolinska   (Sweden)

^f TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER PROGNOSIS; COMPUTER; COMPUTER PROGRAM; CONTROLLED STUDY; DIGITAL IMAGING; DIGITAL SLIDE SCANNER; FEMALE; GENE EXPRESSION ASSAY; HER2 ENRICHED BREAST CANCER; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; ADULT; AGED; BREAST TUMOR; CLASSIFICATION; GENE EXPRESSION PROFILING; IMAGE PROCESSING; MIDDLE AGED; PROCEDURES;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 84959182788     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.34     Document Type: Article

References (47)

1. Schnitt SJ, Lakhani SR, Anderson BO et al. Human cancers by organ site, breast cancer. In: Stewart BW, Wild C (eds). Chapter 5.2. World Cancer Report 2014, pp 508-526
2. Ellis IO, Schnitt SJ, Sastre-Garau X et al. Tumours of the breast. In: Kurman RJ, Carcangiu ML, Herrington CS et al. (eds). Chapter 1. WHO Classification of Tumours of Female Reproductive Organs. International Agency for Research on Cancer. IARC press: Lyon, 2014, pp 9-110
3. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2015;22:1736-1747
4. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2015;24:2206-2223
5. Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015;26:1533-1546
6. Guiu S, Michiels S, Andre F et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 2012 23: 2997-3006
7. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-1167
8. Paquet ER, Hallett MT. Absolute assignment of breast cancer intrinsic molecular subtype. J Natl Cancer Inst 2015;107:357
9. Prat A, Cheang MC, Martin M et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 2013;31:203-209
10. Sgroi DC, Sestak I, Cuzick J et al. Prediction of late distant recurrence in patients with oestrogen-receptorpositive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013;14:1067-1076
11. Bahreini F, Soltanian AR, Mehdipour P. A metaanalysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer. Breast Cancer 2014;22:615-625
12. Cheang MC, Martin M, Nielsen TO et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist 2015;20:474-482
13. Polley MY, Leung SC, Gao D et al. An international study to increase concordance in Ki67 scoring. Mod Pathol 2015;28:778-786
14. Stalhammar G, Rosin G, Fredriksson I et al. Low concordance of biomarkers in histopathological and cytological material from breast cancer. Histopathology 2014;64:971-980
15. Ekholm M, Beglerbegovic S, Grabau D et al. Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility. Histopathology 2014;65:252-260
16. Christgen M, von Ahsen S, Christgen H et al. The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer. Hum Pathol 2015;46:1341-1349
17. Dowsett M, Nielsen TO, AHern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-1664
18. Grabau D, Kovács A, Tolockiene E et al. Quality- and standardization document for breast tumors. Swedish Quality- and Standardization Committee (KVAST) tSPS 2014;1:1-49
19. Romero Q, Bendahl PO, Fernö M et al. A novel model for Ki67 assessment in breast cancer. Diagn Pathol 2014;9:118
20. Klintman M, Bendahl PO, Grabau D et al. The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol 2010;23:251-259
21. Reyal F, Hajage D, Savignoni A et al. Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One 2013;8:e55901
22. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28: 2784-2795
23. Knutsvik G, Stefansson IM, Aziz S et al. Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One 2014;9:e112121
24. Calza S, Hall P, Auer G et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res 2006;8:R34
25. Pawitan Y, Bjöhle J, Amler L et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005;7: R953-R964
26. Al Sarakbi W, Salhab M, Thomas V et al. Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer? Int Semin Surg Oncol 2005;2:15
27. Nadji M, Gomez-Fernandez C, Ganjei-Azar P et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005;123:21-27
28. Cottu PH, Asselah J, Lae M et al. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 2008;19:595-597
29. Yi M, Huo L, Koenig KB et al. Which threshold for ER positivity? A retrospective study based on 9639 patients. Ann Oncol 2014;25:1004-1011
30. Wolff AC., Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31: 3997-4013
31. Anders S, Pyl PT, Huber W. HTSeq - A Python framework to work with high-throughput sequencing data. Bioinformatics 2015;31:166-169
32. Robinson MD, Oshlack A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol 2010;11:R25
33. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-140
34. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70
35. Eroles P, Bosch A, Prez-Fidalgo JA et al. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012;38:698-707
36. Tibshirani R, Hastie T, Narasimhan B et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002;99: 6567-6572
37. Cleary AS, Leonard TL, Gestl SA et al. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 2014;508:113-117
38. Nguyen LV, Pellacani D, Lefort S et al. Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells. Nature 2015;528: 267-271
39. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366: 883-892
40. Krsns A, Strand R, Dor J et al. A histopathological tool for quantification of biomarkers with sub-cellular resolution. Comput Methods Biomech Biomed Eng Imaging Vis 2015;3:25-46
41. Holten-Rossing H, Mller Talman ML, Kristensson M et al. Optimizing HER2 assessment in breast cancer: application of automated image analysis. Breast Cancer Res Treat 2015;152:367-375
42. Laurinaviciene A, Dasevicius D, Ostapenko V et al. Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays. Diagn Pathol 2011;6:87
43. Gavrielides MA, Gallas BD, Lenz P et al. Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computeraided digital microscopy. Arch Pathol Lab Med 2011;135:233-242
44. Rizzardi AE, Johnson AT, Vogel RI et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol 2012;7:42
45. Nielsen PS, Riber-Hansen R, Jensen TO et al. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Mod Pathol 2013;26:404-413
46. Fitzgibbons PL, Dillon DA, Alsabeh R et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med 2014;138:595-601
47. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 1991;19:403-410